Tech Company Financing Transactions

Juno Therapeutics Funding Round

Alaska Permanent Fund, Arch Venture Partners and private investors participated in a $120 million Series A funding round for Juno Therapeutics. The funding round was announced by the company on 12/5/2013.

Transaction Overview

Company Name
Juno Therapeutics
Announced On
12/5/2013
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series A
Investors

Alaska Permanent Fund (Lead Investor) (Michael Burns)

Arch Venture Partners (Lead Investor) (Robert Nelsen)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
307 Westlake Avenue North 300
Seattle, WA 98109
USA
Phone
(206) 582-1600
Website
www.junotherapeutics.com
Email Address
[email protected]
Overview
Juno is a clinical-stage company that brings together three of the world's leading cancer centers -- Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute -- in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Profile
Juno Therapeutics LinkedIn Company Profile
Social Media
Juno Therapeutics Company Twitter Account
Company News
Juno Therapeutics News
Facebook
Juno Therapeutics on Facebook
YouTube
Juno Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Hans Bishop
  Hans Bishop LinkedIn Profile  Hans Bishop Twitter Account  Hans Bishop News  Hans Bishop on Facebook
Chief Financial Officer
Steve Harr
  Steve Harr LinkedIn Profile  Steve Harr Twitter Account  Steve Harr News  Steve Harr on Facebook
Chief Medical Officer
Mark Gilbert
  Mark Gilbert LinkedIn Profile  Mark Gilbert Twitter Account  Mark Gilbert News  Mark Gilbert on Facebook
Chief Scientific Officer
Ken Mohler
  Ken Mohler LinkedIn Profile  Ken Mohler Twitter Account  Ken Mohler News  Ken Mohler on Facebook
VP - General Counsel
Barney Cassidy
  Barney Cassidy LinkedIn Profile  Barney Cassidy Twitter Account  Barney Cassidy News  Barney Cassidy on Facebook
VP - Human Resources
Robin Andrulevich
  Robin Andrulevich LinkedIn Profile  Robin Andrulevich Twitter Account  Robin Andrulevich News  Robin Andrulevich on Facebook
VP - Manufacturing
Andy Walker
  Andy Walker LinkedIn Profile  Andy Walker Twitter Account  Andy Walker News  Andy Walker on Facebook
VP - R & D
Mark Frohlich
  Mark Frohlich LinkedIn Profile  Mark Frohlich Twitter Account  Mark Frohlich News  Mark Frohlich on Facebook
VP - Regulatory Affairs
Elizabeth Smith
  Elizabeth Smith LinkedIn Profile  Elizabeth Smith Twitter Account  Elizabeth Smith News  Elizabeth Smith on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/5/2013: DioGenix venture capital transaction
Next: 12/5/2013: Clever venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.